InnoCare Pharma Ltd (InnoCare) is a biopharmaceutical company that discovers and develops novel treatments for cancer and autoimmune diseases. The company’s pipeline product portfolio includes ICP-022 a Bruton Tyrosine Kinase (BTK) inhibitor to treat B cell malignancies; ICP-105, an inhibitor for the treatment of hepatocellular carcinoma (HCC); ICP-192 a novel compound that targets gene abnormalities in solid tumor. It serves in the therapeutic areas of gastrointestinal cancer, liver cancer, lupus and rheumatoid arthritis. The company builds a fully integrated biopharmaceutical platform with strong in-house research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control. It operates in the US and China. InnoCare is headquartered in Changping, Beijing, China.
Headquarters
China
Address
Building 8, No. 8, Life Science Park Road, Zhongguancun, Life Science Park, Changping District, Beijing, 102206
Telephone
86 10 66609999
No of Employees
1,072
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
9969 (HKG)
Revenue (2022)
$104.4M
18.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
28.8%
(2022 vs 2021)
Market Cap*
$1.1B
Net Profit Margin (2022)
XYZ
39.7%
(2022 vs 2021)
* As of and is in US$
InnoCare Pharma Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Pipeline | Brands: |
| ICP-022- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-cell Lymphoma, Mantle Cell Lymphoma, Central nervous System Lymphoma, Non-Germinal center B-cell Diffuse Large B Cell Lymphoma | InnoCare |
| ICB-B04- Diffuse Large B Cell Lymphoma, Hematology Indications | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In January, the company secured clearance from the U.S. Food and Drug Administration for clinical trial of BCL2 Inhibitor ICP-248. |
| 2023 | Contracts/Agreements | In July, the company and ArriVent Biopharma announced a clinical development collaboration to evaluate the combination of InnoCare’s novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor, ICP-189, with ArriVent’s furmonertinib. |
| 2023 | Regulatory Approval | In April, the company announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in the treatment of patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL). |
Competitor Comparison
| Key Parameters | InnoCare Pharma Ltd | Innovent Biologics Inc | Hainan Haiyao Co Ltd | Ascepion Pharmaceuticals Inc | BeiGene (Beijing) Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Beijing | Suzhou | Haikou | Suzhou | Beijing |
| State/Province | Beijing | Jiangsu | Hainan | Jiangsu | Beijing |
| No. of Employees | 1,072 | 4,872 | 2,247 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jisong Cui | Chief Executive Officer; Chairman | Executive Board | 2019 | 60 |
| Jasmine Cui Ph.D. | Chief Executive Officer; Co Founder; Chairwoman | Executive Board | - | - |
| Renbin Zhao Ph.D. | Vice President - Regulatory Affairs and Clinical Development; Director | Executive Board | 2019 | 54 |
| Xin Fu | Chief Financial Officer | Senior Management | 2023 | - |
| Kevin Gao | Chief Operating Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward